Designing nanomolar antagonists of DC-SIGN-mediated HIV infection: ligand presentation using molecular rods

Stefania Ordanini, Norbert Varga, Vanessa Porkolab, Michel Thépaut, Laura Belvisi, Andrea Bertaglia, Alessandro Palmioli, Angela Berzi, Daria Trabattoni, Mario Clerici, Franck Fieschi and Anna Bernardi

Chem. Commun., 2015, 51, 3816

DC-SIGN antagonists were designed combining one selective monovalent glycomimetic ligand with trivalent dendrons separated by a rigid core of controlled length. The design combines multiple multivalency effects to achieve inhibitors of HIV infection, which are active in nanomolar concentration.